⚠ The Field Force Is a Fixed Cost Against a Variable MarketModerate threat

Intuitive Surgical (ISRG) — threat to the moat

Operating expense is guided to grow 11-13% against procedures at about 14.5%. Those numbers are too close together.

An embedded field organisation is a formidable competitive asset and a large fixed cost that does not shrink when procedures do.

2026 guidance: two rates that are too close together (%)11%Operating expensegrowth, low13%Operating expensegrowth, high13.5%Procedure growth, low15.5%Procedure growth, highHeadcount rose by about 1,383 in 2025. Share-based compensation was $803M, 27% of GAAP operating income.
A decade of operating leverage assumed volume compounding at 18%. At the bottom of one range and the top of the other, it runs backwards.

Intuitive's guidance for 2026 puts the two together explicitly: non-GAAP operating expense growth of 11% to 13%, against da Vinci procedure growth of 13.5% to 15.5% with an expectation of landing nearer the midpoint1. Those numbers are close. If procedure growth comes in at the bottom of the range and expense growth at the top, the operating leverage this company has enjoyed for a decade reverses.

Headcount rose by approximately 1,383 people in 20252, and the fastest-growing part of the organisation is the one that sits in hospitals. That investment is correct when volume is compounding at 18%; it is a different proposition at 12%, which is what the United States delivered in the June quarter3.

There is a second cost pressure inside the same line. Share-based compensation was $803 million in 20254 — 27% of GAAP operating income — which is why GAAP diluted earnings of $2.29 in the June quarter compared with non-GAAP earnings of $2.805. Whichever measure a reader prefers, the gap is a real cost being paid in shares.

The spread between operating expense growth and procedure growth is the thing to follow. Expenses growing faster than procedures for a full year would mean the field organisation had been sized for a market that did not arrive.

References
  1. ReportedIntuitive's guidance for 2026 puts the two together explicitly: non-GAAP operating expense growth of 11% to 13%, against da Vinci procedure growth of 13.5% to 15.5% with an expectation of landing nearer the midpoint.
    Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
  2. ReportedHeadcount rose by approximately 1,383 people in 2025, and the fastest-growing part of the organisation is the one that sits in hospitals.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  3. ReportedThat investment is correct when volume is compounding at 18%; it is a different proposition at 12%, which is what the United States delivered in the June quarter.
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11,710 da Vinci systems up 12%, 468 placements of which 246 were da Vinci 5, the operating-lease share, the distributor acquisitions in Italy, Spain and Portugal, cash and investments of $8.63 billion, and the factors expected to affect future placements) — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  4. ReportedShare-based compensation was $803 million in 2025 — 27% of GAAP operating income — which is why GAAP diluted earnings of $2.29 in the June quarter compared with non-GAAP earnings of $2.80.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - consolidated financial statements and notes (balance sheet, cash and investments, property and equipment, lease arrangements, revenue disaggregation by geography, accounts receivable, share-based compensation and share counts) — FY2025 · publ. February 3, 2026 · source ↗
  5. ReportedShare-based compensation was $803 million in 2025 — 27% of GAAP operating income — which is why GAAP diluted earnings of $2.29 in the June quarter compared with non-GAAP earnings of $2.80.
    Intuitive Surgical second-quarter 2026 results release (Form 8-K exhibit 99.1) - revenue $2,892.3M up 19%, operating income $971.9M, GAAP diluted earnings of $2.29 against non-GAAP $2.80, recurring revenue 85% of the total, and the quarter's procedure and placement figures — Q2 2026 · publ. July 16, 2026 · source ↗
Sources
Generated September 23, 2026